Overview

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 50%. (ROSETTA Lung-202)

Status:
NOT_YET_RECRUITING

Trial end date:
2031-10-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 50%.

Phase:

PHASE3

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

BioNTech SE

Treatments:

pembrolizumab